Johnson & Johnson to buy Auris Health for $3.4 billion
Health products company Johnson & Johnson buys robotics firm Auris Health.
Johnson & Johnson will buy Auris Health, a robotics surgery firm. The health product company’s purchase is worth $3.4 billion in cash.
Why did Johnson & Johnson buy Auris Health?
Johnson & Johnson is the world’s largest health product producer. Auris makes robotic surgery products to assist doctors and has been valued at $2.1 billion. The pharmaceuticals giant is buying the startup to help expand into health technology.
‘This acquisition will accelerate Johnson & Johnson’s entry into robotics with potential for growth and expansion into other interventional applications,’ said Johnson & Johnson in a statement.
Ashley McEnvoy, Johnson & Johnson group chair of consumer medical devices, also explained the purpose of the purchase of Auris Health.
‘In this new era of health care, we're aiming to simplify surgery, drive efficiency, reduce complications and improve outcomes for patients, ultimately making surgery safer. Collectively, these technologies, together with our market-leading medical implants and solutions, create the foundation of a comprehensive digital ecosystem to help support the surgeon and patient before, during and after surgery,’ said McAvoy in a statement.
When will Johnson & Johnson’s purchase of Auris Health be complete?
The purchase of Auris should be completed by Johnson & Johnson by the end of the second quarter. Johnson & Johnson chief executive officer, (CEO), Alex Gorsky, predicts the company will further expand into the billion-dollar surgical instrument business this year and into 2020.
‘What we want to make sure is that we get out in a timely manner, but that we're also out in a manner that ensures we're competitive and ensures, ultimately, that we're making an even bigger difference in this area as we go forward,’ said Gorsky.
This information has been prepared by IG, a trading name of IG Markets Limited. In addition to the disclaimer below, the material on this page does not contain a record of our trading prices, or an offer of, or solicitation for, a transaction in any financial instrument. IG accepts no responsibility for any use that may be made of these comments and for any consequences that result. No representation or warranty is given as to the accuracy or completeness of this information. Consequently any person acting on it does so entirely at their own risk. Any research provided does not have regard to the specific investment objectives, financial situation and needs of any specific person who may receive it. It has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication. Although we are not specifically constrained from dealing ahead of our recommendations we do not seek to take advantage of them before they are provided to our clients.
Seize a share opportunity today
Go long or short on thousands of international stocks.
- Increase your market exposure with leverage
- Get spreads from just 0.1% on major global shares
- Trade CFDs straight into order books with direct market access
Live prices on most popular markets
- Forex
- Shares
- Indices
